| 9.52 -0.48 (-4.8%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.92  |
1-year : | 17.28 |
| Resists | First : | 12.77 |
Second : | 14.8 |
| Pivot price | 10.73 |
|||
| Supports | First : | 9.5 |
Second : | 7.9 |
| MAs | MA(5) : | 10.32 |
MA(20) : | 11.14 |
| MA(100) : | 17.48 |
MA(250) : | 14.45 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 17.9 |
D(3) : | 21.1 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 31 | Low : | 5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTN ] has closed above bottom band by 12.4%. Bollinger Bands are 58.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.06 - 10.12 | 10.12 - 10.18 |
| Low: | 9.34 - 9.41 | 9.41 - 9.47 |
| Close: | 9.76 - 9.87 | 9.87 - 9.99 |
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Tue, 07 Jul 2026
Price to cash flow ratio of Palatin Technologies, Inc. – NASDAQ:PTN - TradingView
Mon, 06 Jul 2026
Tangible book value per share of Palatin Technologies, Inc. – NASDAQ:PTN - TradingView
Sun, 28 Jun 2026
Palatin Technologies, Inc.(NasdaqCM:PTN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Mon, 15 Jun 2026
Palatin Technologies Stock (US69608A1088): Quarterly trends and valuation in focus for PTN - ad-hoc-news.de
Mon, 08 Jun 2026
Palatin Technologies (PTN) Hovers Near Support as Biotech Sentiment Remains Cautious - Triple MA Cross - dars.gov.et
Fri, 29 May 2026
PTN Stock Price and Chart — NASDAQ:PTN - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|